Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,196 matching trials from the live ClinicalTrials.gov search.

Filters: Durham, North Carolina Clear all

Conditions: Bladder Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 285
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Arroyo Grande, California + 197 more

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more

Conditions: Excessive Sleepiness
Interventions: Armodafinil, Matching Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 883 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 128
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 93 more

Conditions: Anemia, Sickle Cell
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 3,640 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 19
States / cities: Oakland, California • San Francisco, California • Miami, Florida + 11 more

Conditions: Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Interventions: Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more

Conditions: Covid19
Interventions: Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Neoplasms
Interventions: Gene-modified (GM) T cell therapy; Genetic
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 104
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
Interventions: US-ATG-F, Placebo; Biological
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 26
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 20 more

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma
Interventions: Laboratory Biomarker Analysis, Taselisib; Other · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1106
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 688 more

Conditions: Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
Interventions: tezosentan, placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 16
States / cities: Huntsville, Alabama • Los Angeles, California • Jacksonville, Florida + 11 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 864
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more

Conditions: Myasthenia Gravis
Interventions: TAK-079, TAK-079 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 27
States / cities: Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more

Conditions: Hepatitis C, Hepatitis C, Chronic
Interventions: thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 54
States / cities: Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more

Conditions: Intracerebral Hemorrhage
Interventions: rt-PA; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 46 more

Conditions: Cardiovascular Disease, de Novo Coronary Lesions
Interventions: TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 53
States / cities: Scottsdale, Arizona • Bakersfield, California • Rancho Mirage, California + 49 more

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1081
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Docetaxel, Durvalumab, Erlotinib Hydrochloride, FGFR Inhibitor AZD4547, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Palbociclib, Pharmacological Study, Rilotumumab, Talazoparib, Taselisib, Tremelimumab; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 1,864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 998
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more

Conditions: Triple Negative Breast Cancer
Interventions: Cisplatin, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 16 more

Conditions: Ventricular Fibrillation, Ventricular Tachycardia, Low Cardiac Output
Interventions: EMBLEM S-ICD System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 1,173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: BI 1467335, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Coronado, California • La Jolla, California • La Mesa, California + 13 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 30
States / cities: Palo Alto, California • San Francisco, California • Miami, Florida + 23 more

Conditions: Parkinson's Disease
Interventions: PYM50028, Placebo; Drug
Lead sponsor: Phytopharm; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more

Conditions: Hepatitis C
Interventions: Daclatasvir, Telaprevir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 19 more

Search by objective public record fields.

Combination Chemotherapy in Treating Patients With Bladder Cancer

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Establishing a Database of People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Data Project [C-Data])

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Tezosentan in the Treatment of Acute Heart Failure

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

A Study of TAK-079 in People With Generalized Myasthenia Gravis

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection